In continuation to the outcome of the Adjourned Board Meeting held on 8th February, 2018, SMS Lifesciences India has informed that the Meeting of the board of directors is scheduled to be held on 23.02.2018, at the registered office of the Company, to consider the Due Diligence report on acquisition of ‘Mahi Drugs’, an API manufacturing company and other related matters thereon.
The above information is a part of company’s filings submitted to BSE.